FC Sciurba, N Siafakas, T Troosters… - American Journal of …, 2011 - Am Thoracic Soc University of Pittsburgh, Pittsburgh, PA, Medical School, University of Crete, Heraklion, Greece, UZ Gasthuisberg, Leuven, Belgium, 1 2 ... Pfizer Inc., New London, CT, Pfizer Inc., New York, NY 5 ... Tiotropium has been shown to produce sustained improvement in ... All 2 versions
[HTML] from gastrojournal.orgJ Bruix, T Poynard, M Colombo, E Schiff, K Burak… - Gastroenterology, 2011 - Elsevier 1 BCLC Group; Liver Unit, Hospital Clinic of Barcelona, University of Barcelona; IDIBAPS, Centro de Investigación Biomédica en Red de Hepatología y Enfermedades Digestivas, Barcelona, Spain. ... 2 Service d'Hepatologie, Université Pierre et Marie Curie Liver Center, Hôpital ... All 4 versions
SD McLaughlin, SK Clark, PP Tekkis… - Colorectal …, 2011 - Wiley Online Library Results Twenty-five patients were identified. The median length of treatment was 15.8 (range 3–62) months. Ten (40%) patients had pouchitis with co-existing prepouch ileitis. The median frequency of defecation was 7 (range 4–11)/24 h, the median clinical Pouch Disease ... Cited by 3 - Related articles - All 2 versions
BJ Schneider, SM Gadgeel, N Ramnath… - Journal of Thoracic …, 2011 - journals.lww.com *Division of Hematology/Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York City, New York; †Thoracic Oncology Program, Division of Hematology/Oncology, Department of Internal Medicine, Karmanos Cancer ... Cited by 1 - Related articles - All 4 versions
HW Herr, G Dalbagni… - European Urology, 2011 - Elsevier Bacillus Calmette-Guérin (BCG) is the standard intravesical treatment of high-risk noninvasive (Ta, T1, Tis) bladder cancer. Maintenance BCG is recommended for maximum efficacy. ... We compared our results in a large cohort of high-risk bladder cancer patients who received ... Cited by 1 - Related articles - All 2 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
